Xenopus postvitellogenic oocytes resume meiosis in vitro upon exposure to insulin or insulin-like growth factor 1 (IGF-1) via a ras-dependent pathway, whereas stage IV (600 mm õ diameter õ 1000 mm) oocytes cannot. The aim of the present study was to determine which event(s) of the transduction pathway from IGF-1 receptor to maturation-promoting factor (MPF) activation is deficient in the small, vitellogenic, oocytes to explain their inability to undergo germinal vesicle breakdown (GVB) after insulin treatment. We thus analyzed the effect of insulin on the Ras/Raf-dependent mitogen-activated protein kinase cascade because of its crucial role prior to MPF activation. The effect of insulin on pp39 mos synthesis in stage IV oocytes was also studied since this protein kinase participates in the mitogen-activated protein kinase ( 
INTRODUCTION
meiosis resumption and progression to metaphase II, wherein oocytes become arrested again until fertilization Ovaries of Xenopus laevis adult females are populated (see Doree, 1990 , for review). Treatments of postvitellowith prophase-I-arrested oocytes at various stages of vitelgenic oocytes with progesterone or insulin/IGF-1 both lead logenesis, from stage I to stage VI (Dumont, 1972) acto the activation of mitogen-activated protein kinase p42 cording to their size. Only late stage V and stage VI oocytes (MAPK; Haccard et al., 1990; Posada and Cooper, 1992 ; (diameter §1100 mm) can undergo maturation upon expo- Gotoh et al., 1995) and maturation-promoting factor sure to progesterone or insulin/insulin-like growth factor (MPF), the latter being responsible for germinal vesicle 1 (IGF-1) (El-Etr et al., 1979; Masui and Clarke, 1979;  breakdown (GVB), chromosome condensation, spindle for- Maller and Koontz, 1981) . This process is refered to as mation, and progression to metaphase II (see Doree, 1990, and Nurse, 1990 , for review). Progesterone-or insulin/IGF-1-induced maturation also requires protein synthesis (Was-1 To whom correspondence should be addressed at UPRES-A serman and Masui, 1995) and, in particular, the synthesis 6026 CNRS, Biologie Cellulaire et Reproduction, Université de Reof pp39 mos (Sagata et al., 1988; , a serine/ nnes 1, Bat. 13, Campus de Beaulieu, Avenue du Gé né ral Leclerc, threonine protein kinase that is a product of the mos pro- tooncogene but the function of which remains unclear dur-ing the early steps of oocyte maturation, i.e., before GVB. Since activation of the Raf-dependent MAP kinase cascade, which lies right downstream of p21 ras in the However, the early events of oocyte maturation partially differ depending on the hormone used. Whereas progesterpathway leading to MPF activation, is required for oocyte maturation (Muslin et al., 1993) , particularly when it is one causes a rapid and transient decrease of the intraoocyte cAMP level due to the inhibition of the adenylate cyclase triggered through a tyrosine kinase receptor pathway (Fabian et al., 1993) , experiments described in this study were (Sadler and Maller, 1981; Cicirelli and Smith, 1985) , followed by a decrease of the activity of PKA, a cAMP-dependesigned to test whether the incompetence of the stage IV oocytes to resume meiosis in response to insulin was due dent protein kinase, insulin or IGF-1 stimulates a cAMP phosphodiesterase (Sadler and Maller, 1989; to their inability to stimulate the Raf r MEK (MAP kinase kinase) r MAPK pathway. In addition, microinjection of 1991) after interacting with a type I IGF receptor in the oocyte membrane (Hainaut et al., 1991; Janicot et al., 1991;  oncogenic p21ras was performed in stage IV oocytes to determine whether this oncogene was capable of activating Scavo et al., 1991) . Furthermore, activation of p21 ras , GAP (GTPase-activating protein), and protein kinases C (PKC) the Raf r MEK r MAPK cascade. Finally, the capacity of these meiotically incompetent oocytes to synthesize are specific events associated with insulin-or IGF-1-induced oocyte maturation. Indeed, microinjection of antipp39 mos was investigated because of the major role of this protooncogene during Xenopus oocyte maturation and bebodies raised against p21 ras blocked insulin-but not progesterone-induced GVB (Deshpande and Kung, 1987; Korn et cause it has been recently reported to be a MAPK kinase kinase like Raf (Nebreda and Hunt, 1993; Posada et al., al., 1987) . A similar result was observed when using a synthetic peptide or azatyrosine that both block GAP activa-1993; Shibuya et al., 1993) . tion (Chung et al., 1991) . The specific implication of PKC in the insulin pathway leading to GVB seems to be important since neomycin, which binds to PI derivatives and
MATERIALS AND METHODS
inhibits the production of DAG and IP3 from the hydrolysis of PIP2, inhibits insulin-or p21 ras -induced maturation (Davis and Sadler, 1992) . Furthermore, stage IV oocytes alvals and scored as mature when a circular unpigmented area (white ready contain all the molecules known to be closely inspot) appeared on the animal pole (Fortune, 1983) . To assess the volved in MPF activation; it includes preMPF, Cdc25 phosdisappearance of the germinal vesicle, the oocytes scored as mature phatase 1994, for review), and also the protein kinase CAK (Brown et al., 1994) , which phosphorylates threonine 161 of p34
cdc2
Plasmid Constructs and in Vitro RNA (see Clarke, 1995, for review) , but MPF would be very Transcription strongly maintained in an inactive form . Altogether, these data suggest that incompetence of small,
The wild-type hraf-1/pSP64T and the truncated D-Nraf/pSP64T
stage IV oocytes to resume meiosis in response to insulin plasmids have been generously provided by D. Morrison and were may be due to some deficiencies in the ''mitogenic'' signal described elsewhere (Fabian et al., 1993) . Both plasmid constructs were linearized with EcoRI restriction enzyme and used as temtransduction between p21 ras and MPF activation.
plates for transcription of 5-capped RNAs using a mCAP mRNA fold diluted oocyte lysate (5 ml, i.e., 12.5 mg proteins; see previous paragraph for extract preparation), the substrate, i.e., 2.6 mg/ml capping kit (Stratagene, Heidelberg, Germany) as specified by the manufacturer. RNA pellets were resuspended in distilled water at histone H1 (Type III S, Sigma) or 2.5 mg/ml myelin basic protein (MBP, Sigma), 20 mM protein kinase A inhibitor (PKI, Sigma), 400 a final concentration of 1.5 mg/ml and stored at 070ЊC until use.
mM cold ATP, and 50 mCi/ml [g-32 P]ATP (4500 Ci/mmol, ICN Pharmaceuticals). Reactions were terminated by adding 20 ml of 21
Oocyte Microinjections
Laemmli sample buffer and heating to 100ЊC for 5 min. PhosphoryStage IV (900 mm õ diameter õ 1000 mm) and stage VI (diameter lation status of both substrates was analyzed by 12.5% SDS-PAGE, ú 1250 mm) oocytes were, respectively, microinjected in the cytothe dried gels being autoradiographed for 12-48 hr at 070ЊC. plasm with approximately 30 and 50 ng capped raf RNAs or 6 and To assay the kinase activity of Raf, it was first necessary to 10 ng oncogenic Ha-Ras lys12, using a Nanoject variable automatic purify a Raf substrate: chinese hamster MEK-1 cDNA (Pages et al., injector (Drummond, Broomall, PA) . Oncogenic Ha-Ras lys12 pro-1994)-subcloned in the EcoRI site of the GST gene fusion vector tein, a generous gift of Drs. M. Pierre and B. Tocque, at a concentrapGEX (Pharmacia Biotech, France)-was a generous gift of Dr. tion of 4 mg/ml was further diluted in microinjection buffer (20 mM Pouyssegur (UMR134/CNRS, University of Nice, France). The vecHepes, pH 7.4, 0.2 mM EDTA, 0.1 M KCl, 20% glycerol).
tor was transfected into competent bacteria Bl21 DE3, and after Oocytes were incubated at 18ЊC in MK/PVP for up to 24 hr. The IPTG induction, GST-MEK was purified from bacterial lysate by GVB rate was then scored and oocytes were homogenized in MPF affinity chromatography on a glutathione Sepharose 4B column buffer for Western blot analyses and in vitro kinase assays.
(Pharmacia Biotech). The fractions of the eluate containing the protein were pooled and dialyzed against 20 mM Hepes, pH 7.4, 20% glycerol, 0.2 mM EDTA, 0.1 M KCl, 1 mM DTT, and protease
Western Blot Analysis
inhibitors (Sigma): 2 mM PMSF, 1 mg/ml leupeptin, and 10 mg/ml Crude oocyte lysates were usually prepared by homogenizing 8 aprotinin. Dialysates were aliquoted and stored at 070ЊC. The assay to 13 oocytes (depending upon the vitellogenic stage considered) of Raf kinase activity was performed under the same conditions as in 40 ml MPF buffer (Cyert and Kirschner, 1988) : 80 mM b-glycerothose used for MAPK or H1K assays after replacing H1 or MBP by phosphate, 20 mM EGTA, 15 mM MgCl 2 , 1 mM dithiothreitol, 20 2.5 ml GST-MEK dialysate. mM Hepes, pH 7.5, containing 0.2 mM PMSF, 0.5 mg/ml leupeptin, and 1 mM sodium orthovanadate. Lysates were centrifugated at 15,000g for 15 min at 4ЊC and the supernatants, which contained 5 mg/ml oocyte proteins, were stored at 070ЊC until use. One vol- We first confirmed that Xenopus 42-kDa MAPK was acti-should also consider the possibility that Raf, which indirectly stimulates MAPK activity via MEK is either absent or cannot be activated by insulin in meiotically incompetent oocytes.
RESULTS

Insulin Does Not Induce Raf Activation in Stage IV Oocytes
It was difficult to quantify the Raf-1 amount in oocytes during vitellogenesis in the same way we did the MEK and MAPK measurements. Immunoblots performed with antiRaf-1 antibodies displayed bands with weaker intensity (even when prolonging the autoradiography up to 10 min) that were thereafter very difficult to analyze densitometrically. Nevertheless, Raf-1 was already detectable in control stage IV oocytes as a doublet with an apparent molecular weight of 68 kDa (Fig. 3A) . Its accumulation reached roughly 50-70% of the Raf content in stage VI oocytes. In insulin-treated stage VI oocytes, Raf shifted to a slower migrating band around the time the oocytes started to undergo GVB, i.e., by 6 hr after addition of the peptide in the experiment displayed in Fig. 3A . At that time, the Raf amount in the oocytes increased too, which confirmed previous observation made during progesterone-induced oocyte maturation (Muslin et al., 1993) . Neither an increase under Materials and Methods. Instead of an expected 75-kDa protein, a mixture of four major polypeptides with molecular weights of 60, 38, 33, and 31 kDa were eluted out of the glutathione Sepharose 4B column and were quantitaThe incapacity of insulin to activate MAPK in small oocytes could be simply explained by a lack of or an insuffitively represented in the following order: p33 ӷ p38 ú p31 ú p60. They were all recognized by an anti-MEK antibody, cient level of MAPK activators. To test this hypothesis, we estimated the content of MEK, the direct upstream activator suggesting they likely were MEK degradation products. In preliminary experiments of in vitro kinase assays, p31, p33, of MAPK, as well as MAPK itself, in oocytes from stage III to stage VI of vitellogenesis. As shown in Fig. 2 , MEK and and p38, but not p60, were phosphorylated by (i) crude extracts of stage VI oocytes that had undergone progesterone-MAPK were already present in stage III oocytes and slowly accumulated up to stage V, but their amount dramatically induced GVB and that were reported to contain activated raf (Fabian et al., 1993; Muslin et al., 1993) and (ii) crude increased at the very end of vitellogenesis, i.e., between stages V and VI, which corresponds to the time oocytes extracts of oocytes microinjected with the constitutively active form of Raf but not by crude extracts of control ''GV'' become competent to resume meiosis. Thus, the amounts of MEK and MAPK in stage IV oocytes represented, respecoocytes (data not shown), suggesting that these three proteins could be used as potential Raf substrates. The results tively, 30 and 59% of what was found in postvitellogenic oocytes. These increases were not related to the increased of a typical in vitro MEK kinase assay displayed in Fig. 3B showed that p33, p31, and p38 (to a lesser extent) were size of the oocytes per se because equal amounts of oocyte proteins were loaded in each lane rather than an equal numstrongly phosphorylated by lysates of stage VI oocytes by the time they started to undergo GVB in response to insulin, ber of oocytes. The low level of MEK protein in particular may, therefore, be a limiting factor in the transduction of whereas none of them were phosphorylated by lysates of stage IV oocytes within the first 12 hr of insulin treatment. insulin mitogenic signal in stage IV oocytes. However, we There was therefore a good correlation between the results and VI oocytes. The results first confirmed previous findings (Fabian et al., 1993; Muslin et al., 1993) : D-NRaf RNA of these in vitro kinase assays (Fig. 3B ) and the immunoblots of the Fig. 3A . These results strengthen the fact that insulin injection into stage VI oocytes led within 24 hr to 32-75% GVB (Table 1) , MPF, and MAPK activation (Figs. 4A and does not activate Raf in stage IV oocytes even though we have not been able to immunoprecipitate an active form of 4B, respectively), while oocytes injected with the same amount of RNA encoding the wild-type form of Raf reRaf in the oocyte lysates, after using two different antibodies, to prove that this kinase was responsable in our extracts mained in the GV stage and thus behaved as control noninjected oocytes, except for 2 of 190 ( 
MAPK Activation
ing these small oocytes, D-NRaf stimulated MAP kinase activity as illustrated by the increase of MBP kinase activity We then asked whether stage IV oocytes would be able to undergo GVB if Raf was activated. To address this question, (Fig. 4B) as well as the typical retarded mobility of the molecule on a 15% polyacrylamide gel (Fig. 4C) . These results capped D-NRaf RNA coding for a truncated form of Raf that lacks the regulatory domain and therefore is expressed indicated that (i) the low content of MEK in stage IV oocytes was not a limiting factor in mediating Raf-induced MAPK as a constitutively active kinase was injected into stage IV
Neither Constitutively Active Raf (D-NRaf) nor Insulin Stimulate pp39 mos Synthesis in Stage IV Oocytes
Since it has been recently hypothesized that MAPK may stimulate pp39 mos synthesis (Matten et al., 1996; Roy et al., 1996) and 5B), especially in those that had undergone GVB. In a second experiment, oocyte extracts were made 6, 12, and 24 hr after microinjection to determine which of MAPK or Mos synthesis was stimulated first. As illustrated in Fig.  5B , MAPK started to shift at 6 hr postinjection and was totally under the active form by 12 hr, whereas Mos was barely detectable, its accumulation dramatically increasing between 12 and 24 hr. These results showed that MAPK activation preceded Mos accumulation. Finally, we compared Mos accumulation in stage IV versus stage VI oocytes after stimulation by 5 mM insulin. Mos became detectable in postvitellogenic oocytes as soon as 2 hr after insulin stimulation and its accumulation peaked by the time (8 hr) 62.5% of the oocytes had undergone GVB (Fig. 6 ), which confirmed previous observations (Roy et al., 1996) about Mos synthesis during progesterone-induced maturation. In contrast, Mos could not be detected in insulin-treated stage IV oocytes within 12 hr of exposure, which reinforced the fact that stage IV oocytes are not able to synthesize pp39 mos . In view of these last results, we could not exclude that phosphorylation of MEK polypeptides p31, p33, and p38 by crude extracts of insulin-treated postvitellogenic oocytes (Fig. 3B ) was due to Mos rather than Raf since both MEK oocytes upon exposure to insulin. Oocytes at both stages of develkinases appear to be activated around the same time in opment were incubated in MK/PVP in presence of 5 mM insulin for 12 hr and oocytes (13, stage IV, or 8, stage VI) were lysed in 40 ml MPF buffer every 2 hr. Oocyte lysates were then probed with an anti-Raf-1 antibody used at a 1:200 dilution (A) or analyzed in a animal pole and therefore were scored as GVB oocytes. They were lysed to be used in Western blots and kinase assays a The number of oocytes that had undergone GVB was scored 24
and thus could not be fixed to assess disappearance of the hr after microinjection.
GV. Since no H1 kinase activity was detected in the lysate b Stage IV (900 mm õ diameter õ 1000 mm) and stage VI (diameter containing these four oocytes (data not shown), it was con-ú 1250 mm) denuded oocytes were, respectively, microinjected into cluded that they had been misscored and that the white had migrated up near the oocyte membrane.
Microinjection of Ha-Ras lys12 Protein into Stage IV Oocytes neither Triggers GVB nor Mos Synthesis but Does Induce Raf and MAPK Activation
In order to be activated, Raf must be translocated first to the oocyte membrane by activated Ras-GTP, where it is then phosphorylated by Raf-activating factor(s), the nature of which remains to be elucidated. The simplest explanations for the inability of insulin to stimulate Raf activity and subsequent MAPK cascade in stage IV oocytes are that activated Ras does not properly target Raf to the membrane   FIG. 4 . Effect of D-NRaf RNA injection in stage IV and stage VI oocytes on H1 kinase and MAP kinase activities. Stage IV and VI oocytes were microinjected, respectively, with 30 and 50 ng DNRaf RNA (DN) or wild-type Raf RNA (wt) as control RNA. After a 24-hr incubation in MK/PVP, GVB was scored and oocytes (13, stage IV, or 8, stage VI) were lysed in 40 ml MPF buffer; in the group of stage VI oocytes injected with D-NRaf RNA, only those that had undergone GVB were lysed. A group of noninjected oocytes (n.i.) was also used as control. The same oocytes lysates were either analyzed in a H1 kinase (A) or a MBP kinase assay (B) or probed with an anti-ERK2 antibody used at a 1:1000 dilution (C) as described under Materials and Methods. These results are representative of at least three independent experiments. these oocytes. To test this hypothesis, the same kinase assay was performed with crude extracts of stage IV and VI oocytes previously injected with D-NRaf mRNA since, contrary to stage VI oocytes, no Mos protein could be detected in stage IV oocytes. Figure 7 shows that only p31 was phosphorylated by stage IV oocyte extracts as soon as (Fig. 5B ). In addition, microinjecincubation in MK/PVP, GVB was scored and oocytes (13, stage IV, tion in stage VI oocytes of Ras lys12 , which is known to or 8, stage VI) were lysed in 40 ml MPF buffer; in the group of stage VI oocytes injected with D-NRaf RNA, oocytes that had undergone quickly activate Raf in several cell types, led to similar GVB were homogenized separately from those that had not, n.i., results, i.e., phosphorylation of p31 first, followed by that non-injected oocytes. (B) Stage VI oocytes were microinjected with of p33 and p38 by the time Mos was neosynthesized (data 50 ng of either D-NRaf or wild-type Raf RNA (wt). 8 oocytes were not shown). These data strongly suggest that in our in vitro lysed before (0) or 6, 12, and 24 hr following microinjection. In both kinase assay shown in Fig. 3B , phosphorylation of MEK p31
series (A and B), the oocytes lysates were probed with an anti-Mos xe accounts for Raf activation, whereas that of p33 and p38
antibody used at a 1:500 dilution or with an anti-ERK2 antibody, account for Mos activation, unless a third MEK kinase is to detect p42 MAPK, used at a 1:1000 dilution, as described under activated in insulin-treated oocytes. Such a kinase has not Materials and Methods. These results are representative of at least three independent experiments. yet been characterized in Xenopus oocytes. Rime et al., 1995) and probably downstream of the p21 ras system (Davis and Sadler, 1992) when insulin is used to induce maturation. Like MPF, MAPK is a protein kinase which plays a central role during oocyte maturation in vertebrates. However, in Xenopus, a controversy has long remained about which of MAPK or MPF was activated first in the cascade of events leading to GVB. It is now well understood that MAPK activation, which is undoubtedly necessary for the progression from meiosis I to meiosis II and for metaphase II arrest , is also required prior GVB to activate MPF (see Gotoh and Nishida, 1995, for review) . In view of these data, we investigated whether a dysfunction of the MAPK pathway could be the source of the meiotic incompetence of stage IV oocytes. The insulin cannot stimulate MAPK activity in these small oo- Mos synthesis in stage IV oocytes.
are representative of at least three independent experiments.
The fact that constitutively active Raf could activate MAPK in stage IV oocytes whereas insulin could not, combined with observations of Davis and Sadler (1992) demonstrating that p21
ras system was present in stage IV oocytes and/or Raf stimulators are not present. To verify this hyand was recruited to the oocyte membrane after insulin pothesis, we injected oncogenic Ras, Ha-Ras lys12, both in treatment, first led us to postulate that the inability of insustage IV and stage VI oocytes and assayed Raf, MAP kinase, lin to stimulate the MAPK pathway was due to an interrupand H1 kinase activities as well as Mos accumulation (Fig. tion of the transduction pathway between Ras and Raf. 8). Contrary to stage VI oocytes, none of the stage IV oocytes However, this hypothesis is invalidated by our present reresumed meiosis upon microinjection of Ha-Ras lys12, even sults showing that microinjection of oncogenic Ras in stage 24 hr after the injection. This was ascertained by the ab-IV oocytes elicited a stimulation of both Raf and MAPK as sence of GVB and H1 kinase activation, which confirmed quickly as in stage VI oocytes (Fig. 8) ; rather, it indicates previous results by Johnson et al. (1990) . However, MAP that insulin cannot activate Ras in stage IV oocytes. Ras Kinase was activated in a similar fashion in both types of activation is a complex mechanism which requires the conoocytes as soon as 6 hr after Ha-Ras lys12 microinjection version from the GDP-bound (inactive) to the GTP-bound (Fig. 8B) . Moreover, in the MEK kinase assay, MEK p31 was phosphorylated in stage IV oocytes with a similar time course but sometimes with a smaller amplitude than in stage VI oocytes (Fig. 8A) , strongly suggesting that oncogenic Ras activates Raf-dependent MAP kinase cascade in stage IV as in stage VI oocytes. Finally, as shown after microinjecting Raf RNA (Figs. 5A and 7) , a correlation between MEK p33 and p38 in vitro phosphorylation and pp39Mos accumulation (Fig. 8D ) was again observed in Ras-microinjected stage VI oocytes, whereas none of these two polypeptides were phosphorylated by injected stage IV oocyte extracts, in which no Mos protein could be detected within 24 hr after microinjection. Incompetence of Xenopus stage IV oocytes to resume mei-MEK kinase activity was measured in crude extracts using MEK osis has been so far explained by a dysfunction of event (s) p31, p33, and p38 as substrates, as described under Materials and Methods and in the legend to Fig. 3B . acting prior to MPF activation (Sadler and Maller, 1983;  Indeed, the fact that both constitutively active Raf, expressed after microinjection of D-NRaf RNA, and oncogenic Ha-Ras lys12 did not trigger GVB in stage IV oocytes although MAPK was activated as well as in Ras-or Rafinjected fully grown oocytes clearly indicates that MAPK activation, if necessary, is not sufficient for these small oocytes to undergo GVB. At first sight, the inefficiency of Ras and Raf to induce GVB in stage IV oocytes could be explained by the absence of Mos accumulation following MAPK activation, whereas such accumulation was observed in Ras-or Raf-injected postvitellogenic oocytes prior GVB. However, two reports first showed that Raf-induced GVB did not require Mos synthesis since coinjection of mos antisense oligonucleotide did not prevent Raf-injected stage VI oocytes from undergoing GVB (Fabian et al., 1993; Muslin et al., 1993) . Moreover, GVB induced after microinjection in stage VI oocytes of Ha-Ras lys12 could still be observed when these oocytes were incubated in presence of cycloheximide at a concentration (2 mg/ml) which blocks protein synthesis (Allende et al., 1988; Nebreda et al., 1993; our unpublished observations) . Therefore, the inability of Ras and Raf to induce GVB in stage IV oocytes may rather be due to the dysfunction of a still unknown mechanism(s) that directly connects MAPK to preMPF r MPF conversion. of the mitogenic signal into several parallel pathways that include MAPK, Mos, and Cdc25, the combined activation of which may likely lead to GVB (Fig. 9) .
Mos accumulation, which peaks in Xenopus stage VI oocytes around the time they undergo GVB in response either (active) form. Two major proteins seem so far to participate in the activation of Ras: the GTP/GDP exchange protein Sos to progesterone (Sagata et al., 1989; Roy et al., 1996) or insulin (our present results, Fig. 6 ) and which is required and the 120-kDa protein GAP (Baltensperger et al., 1993) . As stage IV and stage VI oocytes display comparable levels of during progesterone-as well as insulin-induced meiotic maturation in Xenopus oocytes (Sagata et al., 1988; Barrett GAP activity (Davis and Sadler, 1992) , the inability of insulin to activate Ras in stage IV oocytes may be caused by a et al., 1990), has been reported to be directly and positively regulated by MAPK (Matten et al., 1996; Roy et al., 1996) dysfunction in the cascade of events linking IGF-1R to Sos, which involves docking proteins like Shc and IRS-1 and via a yet unknown mechanism. We confirmed this role of MAPK when showing that constitutively active Raf exthe adaptor molecule Grb2 (see Grigorescu et al., 1994, for review) . Effects of insulin on Ras GTP loading and on repressed in postvitellogenic oocytes did induce Mos accumulation a few hours after stimulating MAPK and that the cruitment of Sos in the membrane of stage IV versus stage VI oocytes are currently being investigated in our laboratory dramatic increase of Mos content in insulin-treated oocytes coincided with MAPK activation. From our results, it canto better understand how these upstream elements of the insulin signaling pathway take place during acquisition of not be excluded that Mos accumulation results from MAPK-induced MPF activation instead of being directly meiotic competence.
Nevertheless, the absence of Raf-dependent MAPK actistimulated by MAPK (Fig. 9) . However, since Mos started to be detected in postvitellogenic oocytes as soon as 2 hr vation in stage IV oocytes exposed to insulin cannot alone account for the inability of the hormone to trigger GVB. after hormone addition, i.e., at a time MAPK was not yet , it appears that the Ras/Raf/MEK/MAPK pathway is functional but (i) Ras cannot be activated, (ii) Mos synthesis cannot be stimulated, and (iii) an active MAPK cannot induce MPF activation.
activated, there must be a MAPK-independent mechanism ACKNOWLEDGMENTS that allows early synthesis of pp39 mos during oocyte maturation. This hypothesis is strengthened by a recent report vated. It suggests that Mos synthesis cannot be initiated in these small oocytes whatever the activator, early or late, is. We can rule out the possibility that stage IV oocytes have
